Floatz logo

shr0302

Resistance to Immunotherapy

First Affiliated Hospital of Chongqing Medical UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

180 Active assets in the Resistance to Immunotherapy cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Sugemalimab
Second Affiliated Hospital of Soochow University
Phase 2BB

View all 50 →

Same molecule, other indications

shr0302 is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
55 / 100
View asset →
immune system disorderDormant
CCC
Indicative ·
53 / 100
View asset →
ImmunomodulationDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →